LL-37 vs Thymosin Beta-4
A side-by-side research comparison of LL-37 and Thymosin Beta-4 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | LL-37 | Thymosin Beta-4 |
|---|---|---|
| Full name | Cathelicidin Antimicrobial Peptide LL-37 | Thymosin Beta-4 (Full Length) |
| Category | Healing & Recovery | Healing & Recovery |
| Status | Research compound | Research compound |
| Mechanism | Disrupts microbial membranes, neutralizes endotoxins, recruits immune cells via chemotaxis, and promotes angiogenesis and re-epithelialization. | Sequesters G-actin to regulate cytoskeleton dynamics, promotes stem cell differentiation, and activates anti-inflammatory and anti-apoptotic pathways. |
| Molecular weight | 4493.33 Da | 4921 Da |
| Half-life | ~4-6 hours | ~6-8 hours |
| Bioavailability | Variable by route; topical and injectable | ~95% subcutaneous |
| Typical dose | 50-100 mcg | 1-5 mg |
| Frequency | Daily | 2-3x per week |
| Route | Topical or subcutaneous injection | Subcutaneous injection |
LL-37 reported benefits
- Broad-spectrum antimicrobial
- Wound healing acceleration
- Biofilm disruption
- Immune system enhancement
Thymosin Beta-4 reported benefits
- Comprehensive tissue repair
- Cardiac regeneration
- Neurological recovery
- Corneal healing
- Anti-fibrotic effects
Related comparisons
Research and educational reference only. Not medical advice.